CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
OPERATING EXPENSES
General and administrative	$ 1,757	$ 1,453
Research and development	1,182	3,071
Total operating expenses	2,939	4,524
Interest and other expenses (income), net	24	43
Loss from operations before taxes	2,963	4,567
Income tax benefit	(192)	(400)
Net Loss	2,771	4,167
Less: Net Loss attributable to the noncontrolling interest	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 2,771	$ 4,167
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.07	$ 0.10
Basic and diluted shares outstanding (in shares)	40,885	40,885